DYNDyne Therapeutics, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$52M

Net Income

-$52M

EPS (Diluted)

$-1.00

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$30M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$426M

Total Liabilities

$57M

Stockholders' Equity

$368M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$52M	-$29M	-81.7%
Net Income	-$52M	-$29M	-80.8%

DYN Q4 2021 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena